The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Molecular mechanisms and clinical applications of angiogenesis
Open accessAbstract
Blood vessels deliver oxygen and nutrients to every part of the body, but also nourish diseases such as cancer. Over the past decade, our understanding of the molecular mechanisms of angiogenesis (blood vessel growth) has increased at an explosive rate and has led to the approval of anti-angiogenic drugs for cancer and eye diseases. So far, hundreds of thousands of patients have benefited from blockers of the angiogenic protein vascular endothelial growth factor, but limited efficacy and resistance remain outstanding problems. Recent preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In clinical settings, this approach has been proven to be ineffective when used alone [23].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [23]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [184]
Experimental — accuracy not yet measuredIn the citing paper
“This disparity is, in part, attributed to VEGF-independent nonangiogenic mechanisms of vascularization (such as vessel co-option) that are exploited by cancer cells at the early stages of metastasis formation6,9,55,56”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [9]
In the citing paper
“Several cellular and molecular mechanisms of escape from antiangiogenic therapies have been postulated and investigated, including activation of alternative angiogenic pathways, recruitment of proangiogenic myeloid cells, increased pericyte cell coverage of tumour blood vessels, increased tumour cell invasion, and alternative modes of vessel recruitment7,9,80”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Tumour vessels become abnormal in almost all aspects of their structure and functio”
BackgroundSelf-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,379
Self-citationIntegrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2748 · Cited by 3,815
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,551
Self-citationVEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“Aberrant FGF signalling promotes tumour angiogenesis and mediates the escape of tumour vascularization from VEGF- or epidermal growth factor receptor (EGFR)-inhibitor treatmen”
BackgroundMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,594
Self-citationHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Pàez‐Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,373
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,299
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationThe FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N. R., Crystal, R. G., Besmer, P., Lyden, D. C., Moore, M. A. S., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00754-7 · Cited by 1,744
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz‐Muñoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,739
Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., Mol, M. D., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,708
Self-citationControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Koh, G. Y., Thurston, G., & Alitalo, K. K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,512
Lymphangiogenesis: Molecular Mechanisms and Future Promise
Tammela, T., & Alitalo, K. K. (2010) · Cell · doi:10.1016/j.cell.2010.01.045 · Cited by 1,485
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Glioblastoma stem-like cells give rise to tumour endothelium
Wang, R., Chadalavada, K., Wilshire, J. A., Kowalik, U., Hovinga, K. E., Geber, A. B., Fligelman, B., Leversha, M. A., Brennan, C., & Tabar, V. S. (2010) · Nature · doi:10.1038/nature09624 · Cited by 1,253
uPAR: a versatile signalling orchestrator
Blasi, F., & Carmeliet, P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm977 · Cited by 1,224
Self-citationBergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Du, R., Lu, K. V., Petritsch, C. K., Liu, P., Ganß, R., Passegue, E. A., Song, H., VandenBerg, S. R., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,166
The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis
Benedito, R., Roca, C., Sörensen, I., Adams, S., Gossler, A., Fruttiger, M., & Adams, R. H. (2009) · Cell · doi:10.1016/j.cell.2009.03.025 · Cited by 1,138
HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α
Arany, Z., Foo, S.-Y., Ma, Y., Ruas, J. L., Bommi-Reddy, A., Girnun, G., Cooper, M., Laznik, D., Chinsomboon, J., Rangwala, S. M., et al. (2008) · Nature · doi:10.1038/nature06613 · Cited by 1,054
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,047
Self-citationAutocrine VEGF Signaling Is Required for Vascular Homeostasis
Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S. P., Ferrara, N., Nagy, A., Roos, K. P., & Iruela‐Arispe, M. L. (2007) · Cell · doi:10.1016/j.cell.2007.06.054 · Cited by 1,041
Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting
Jakobsson, L., Franco, C. A., Bentley, K., Collins, R., Ponsioen, B., Aspalter, I. M., Rosewell, I. R., Busse, M., Thurston, G., Medvinsky, A., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2103 · Cited by 1,020
Endothelial-Mural Cell Signaling in Vascular Development and Angiogenesis
Gaengel, K., Genové, G., Armulik, A., & Betsholtz, C. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.161521 · Cited by 933
Angiogenesis: A Team Effort Coordinated by Notch
Phng, L., & Gerhardt, H. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.015 · Cited by 866
Mazzone, M., Dettori, D., de Oliveira, R. L., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A. A., Pollard, P. J., de Almodóvar, C. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.020 · Cited by 828
Self-citationRapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R. B., Norberg, S. M., O’Brien, S., Sennino, B., Nakahara, T., Yao, V., Inai, T., Brooks, P. C., Freimark, B. D., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 814
Escudier, B. J., Joaquim Bellmunt, B., Négrier, S., Bajetta, E., Melichar, B., Sergio Bracarda, A., Ravaud, A., Golding, S., Jethwa, S., & Šneller, V. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7849 · Cited by 802
Dejana, E., Tournier‐Lasserve, E., & Weinstein, B. M. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.004 · Cited by 787
Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695 · cited 1×
“By skewing the polarization of tumour-associated macrophages (TAMs), the loss of PlGF improves vessel perfusion and maturation, and enhances responses to chemotherap”
BackgroundSelf-citationCrawford, Y., Kasman, I. M., Yu, L., Zhong, C., Wu, X., Modrusan, Z. D., Kaminker, J. S., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 635
Allegra, C. J., Yothers, G., O’Connell, M. J., Sharif, S., Petrelli, N. J., Colangelo, L. H., Atkins, J. N., Seay, T. E., Fehrenbacher, L., Goldberg, R. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0855 · Cited by 590
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2524 · Cited by 582
Self-citationButler, J. M., Kobayashi, H., & Rafii, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2791 · Cited by 578
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Self-citationEphrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis
Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker‐Palmer, A. (2010) · Nature · doi:10.1038/nature08995 · Cited by 551
Song, S., Ewald, A. J., Stallcup, W. B., Werb, Z., & Bergers, G. (2005) · Nature Cell Biology · doi:10.1038/ncb1288 · Cited by 551
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Plotkin, S. R., Stemmer-Rachamimov, A. O., Barker, F. G., Halpin, C. F., Padera, T. P., Tyrrell, A., Sorensen, A. G., Jain, R. K., & di Tomaso, E. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902579 · Cited by 537
Self-citationVascular endothelial growth factor B controls endothelial fatty acid uptake
Hagberg, C. E., Falkevall, A., Wang, X., Larsson, E., Huusko, J., Nilsson, I., van Meeteren, L. A., Samén, E., Lu, L., Vanwildemeersch, M., et al. (2010) · Nature · doi:10.1038/nature08945 · Cited by 508
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
Stockmann, C., Doedens, A. L., Weidemann, A., Zhang, N., Takeda, N., Greenberg, J. I., Cheresh, D. A., & Johnson, R. S. (2008) · Nature · doi:10.1038/nature07445 · Cited by 489
VEGF-A and the Induction of Pathological Angiogenesis
Nagy, J. A., Dvořàk, A. M., & Dvorak, H. F. (2007) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.134925 · Cited by 483
Saharinen, P., Eklund, L., Miettinen, J., Wirkkala, R., Anisimov, A., Winderlich, M., Nottebaum, A., Vestweber, D., Deutsch, U., Koh, G. Y., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1715 · Cited by 471
Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities
Hida, K., Hida, Y., Amin, D. N., Flint, A., Panigrahy, D., Morton, C. C., & Klagsbrun, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1567 · Cited by 470
Visentin, B., Vekich, J. A., Sibbald, B. J., Cavalli, A. L., Moreno, K. M., Matteo, R., Garland, W. A., Lu, Y., Yu, S., Hall, H. S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.023 · Cited by 464
Arterial–Venous Specification During Development
Swift, M. R., & Weinstein, B. M. (2009) · Circulation Research · doi:10.1161/circresaha.108.188805 · Cited by 442
MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis
Nicoli, S., Standley, C., Walker, P., Hurlstone, A. F. L., Fogarty, K. E., & Lawson, N. D. (2010) · Nature · doi:10.1038/nature08889 · Cited by 441
The semaphorins: versatile regulators of tumour progression and tumour angiogenesis
Neufeld, G., & Kessler, O. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2404 · Cited by 427
Axon Guidance Molecules in Vascular PatterningPreprint
Adams, R. H., & Eichmann, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001875 · Cited by 427
Regulation of Angiogenesis by Oxygen and Metabolism
Fraisl, P., Mazzone, M., Schmidt, T., & Carmeliet, P. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.003 · Cited by 424
Self-citationCXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., & Jain, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2636 · Cited by 414
Self-citationSignaling by members of the TGF-β family in vascular morphogenesis and disease
Pardali, E., Goumans, M., & ten Dijke, P. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.06.006 · Cited by 402
Cellular and Molecular Mechanisms of Vascular Lumen Formation
Iruela‐Arispe, M. L., & Davis, G. E. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.013 · Cited by 395
The Molecular Basis of Vascular Lumen Formation in the Developing Mouse Aorta
Strilić, B., Kučera, T., Eglinger, J., Hughes, M. R., McNagny, K. M., Tsukita, S., Dejana, E., Ferrara, N., & Lammert, E. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.08.011 · Cited by 389
Schaper, W. K. A. (2008) · Basic Research in Cardiology · doi:10.1007/s00395-008-0760-x · Cited by 388
Lichtenberger, B. M., Tan, P. K., Niederleithner, H., Ferrara, N., Petzelbauer, P., & Sibilia, M. C. (2010) · Cell · doi:10.1016/j.cell.2009.12.046 · Cited by 370
Lebrin, F., Srun, S., Raymond, K., Martín, S., van den Brink, S., Freitas, C., Bréant, C., Mathivet, T., Larrivée, B., Thomas, J., et al. (2010) · Nature Medicine · doi:10.1038/nm.2131 · Cited by 365
Herbert, S. P., Huisken, J., Kim, T. N., Feldman, M. E., Houseman, B. T., Wang, R. A., Shokat, K. M., & Stainier, D. Y. R. (2009) · Science · doi:10.1126/science.1178577 · Cited by 354
Nrarp Coordinates Endothelial Notch and Wnt Signaling to Control Vessel Density in Angiogenesis
Phng, L., Potente, M., Leslie, J. D., Babbage, J. W., Nyqvist, D., Lobov, I. B., Ondr, J. K., Rao, S., Lang, R. A., Thurston, G., et al. (2009) · Developmental Cell · doi:10.1016/j.devcel.2008.12.009 · Cited by 349
The Role of Wnt Signaling in Physiological and Pathological Angiogenesis
Dejana, E. (2010) · Circulation Research · doi:10.1161/circresaha.110.223750 · Cited by 347
VEGF-A: a critical regulator of blood vessel growth
Ferrara, N. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0170 · Cited by 346
Pathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 324
Corada, M., Nyqvist, D., Orsenigo, F., Caprini, A., Giampietro, C., Taketo, M. M., Iruela‐Arispe, M. L., Adams, R. H., & Dejana, E. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.006 · Cited by 324
The FGF system has a key role in regulating vascular integrity
Murakami, M., Nguyen, L. T., Zhang, Z. W., Moodie, K. L., Carmeliet, P., Stan, R. V., & Simons, M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35298 · Cited by 318
Self-citationEssential Regulation of CNS Angiogenesis by the Orphan G Protein–Coupled Receptor GPR124
Kuhnert, F., Mancuso, M. R., Shamloo, A., Wang, H.-T., Choksi, V., Florek, M., Su, H., Fruttiger, M., Young, W. L., Heilshorn, S. C., et al. (2010) · Science · doi:10.1126/science.1196554 · Cited by 301
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera‐Troise, I., & Yancopoulos, G. D. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2130 · Cited by 297
Chronic DLL4 blockade induces vascular neoplasms
Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P., Zhang, G., Ridgway, J. B., Niessen, K., & Plowman, G. D. (2010) · Nature · doi:10.1038/nature08751 · Cited by 280
Hellberg, C. B., Östman, A., & Heldin, C. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-78281-0_7 · Cited by 272
The shunt problem: control of functional shunting in normal and tumour vasculature
Pries, A. R., Höpfner, M., le Noble, F. A. C., Dewhirst, M. W., & Secomb, T. W. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2895 · Cited by 264
de Veire, S. V., Stalmans, I., Heindryckx, F., Oura, H., Tijeras‐Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.039 · Cited by 255
Self-citationDeryugina, E. I., & Quigley, J. P. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.09.017 · Cited by 239
VEGF Receptor 2 Endocytic Trafficking Regulates Arterial Morphogenesis
Lanahan, A. A., Hermans, K., Claes, F., Kerley-Hamilton, J. S., Zhuang, Z. W., Giordano, F. J., Carmeliet, P., & Simons, M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.02.016 · Cited by 228
Self-citationFalcón, B. L., Hashizume, H., Koumoutsakos, P., Chou, J., BREADY, J. V., Coxon, A., Oliner, J. D., & McDonald, D. M. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090391 · Cited by 225
di Tomaso, E., Snuderl, M., Kamoun, W. S., Duda, D. G., Auluck, P. K., Fazlollahi, L., Andronesi, O. C., Frosch, M. P., Wen, P. Y., Plotkin, S. R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2602 · Cited by 201
Self-citationMcCarty, M. F., Somcio, R., Stoeltzing, O., Wey, J. S., Fan, F., Liu, W., Bucana, C. D., & Ellis, L. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31334 · Cited by 182
Pericytes: gatekeepers in tumour cell metastasis?
Gerhardt, H., & Semb, H. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0258-2 · Cited by 172
Miles, D., Harbeck, N., Escudier, B. J., Hurwitz, H. I., Saltz, L. B., Cutsem, E. V., Cassidy, J., Mueller, B., & Sirzén, F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2794 · Cited by 161
PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
Bais, C., Wu, X., Yao, J. J., Yang, S., Crawford, Y., McCutcheon, K. M., Tan, C., Kolumam, G. A., Vernes, J.-M., Eastham‐Anderson, J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.033 · Cited by 159
Koh, Y. J., Kim, H.-Z., Hwang, S.-I., Lee, J. E., Oh, N., Jung, K., Kim, M., Kim, K. E., Kim, H., Lim, N. K., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.001 · Cited by 157
αvβ3 integrin and angiogenesis: a moody integrin in a changing environment
Hodivala‐Dilke, K. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.06.007 · Cited by 154
Bry, M., Kivelä, R., Holopainen, T., Anisimov, A., Tammela, T., Soronen, J., Silvola, J. M. U., Saraste, A., Jeltsch, M., Korpisalo, P., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.957332 · Cited by 151
Self-citationTvorogov, D., Anisimov, A., Zheng, W., Leppänen, V., Tammela, T., Laurinavičius, S., Holnthoner, W., Heloterä, H., Holopainen, T., Jeltsch, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.001 · Cited by 135
Eph Receptors and Ephrin Ligands: Important Players in Angiogenesis and Tumor Angiogenesis
Mosch, B., Reißenweber, B., Neuber, C., & Pietzsch, J. (2010) · Journal of Oncology · doi:10.1155/2010/135285 · Cited by 120
di Tomaso, E., London, N. R., Fuja, D. G., Logie, J. J., Tyrrell, J. A., Kamoun, W. S., Munn, L. L., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005123 · Cited by 116
Self-citationNagengast, W. B., Hooge, M. N. L., Oosting, S. F., den Dunnen, W. F. A., Warnders, F.-J., Brouwers, A. H., de Jong, J. R., Price, P., Hollema, H., Hospers, G. A. P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1088 · Cited by 113
Padera, T. P., Kuo, A. H., Hoshida, T., Liao, S., Shah, J. L., Kozak, K. R., Fukumura, D., & Jain, R. K. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0182 · Cited by 109
Self-citationControl of cardiovascular differentiation by microRNAs
Ohtani, K., & Dimmeler, S. (2010) · Basic Research in Cardiology · doi:10.1007/s00395-010-0139-7 · Cited by 102
Vascular endothelial growth factor receptor‐1 in human cancer
Schwartz, J. D., Rowinsky, E. K., Youssoufian, H., Pytowski, B., & Wu, Y. L. (2010) · Cancer · doi:10.1002/cncr.24789 · Cited by 95
Pericytes: Blood-Brain Barrier Safeguards against Neurodegeneration?
Quaegebeur, A., Segura, I., & Carmeliet, P. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.024 · Cited by 91
Self-citationNisancioglu, M. H., Betsholtz, C., & Genové, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4245 · Cited by 87
Role of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration.
Heissig, B., Nishida, C., Tashiro, Y., Sato, Y., Ishihara, M., Ohki, M., Gritli, I., Rosenkvist, J., & Hattori, K. (2010) · PubMed · doi:10.14670/hh-25.765 · Cited by 73
Genetics, epigenetics and pharmaco‐(epi)genomics in angiogenesis
Buysschaert, I., Schmidt, T., Roncal, C., Carmeliet, P., & Lambrechts, D. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00515.x · Cited by 64
Self-citationSennino, B., Kuhnert, F., Tabruyn, S. P., Mancuso, M. R., Hu‐Lowe, D. D., Kuo, C. J., & McDonald, D. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3779 · Cited by 55
Integrins as “functional hubs” in the regulation of pathological angiogenesis
Contois, L. W., Akalu, A., & Brooks, P. C. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.002 · Cited by 43
Premetastatic Lung “Niche”: Is Vascular Endothelial Growth Factor Receptor 1 Activation Required?
Duda, D. G., & Jain, R. K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0119 · Cited by 37
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Breton, A. L., & Véronique Préat, A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 4,006
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
Self-citationMao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Metadata
- Authors
- Carmeliet, P., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Carmeliet, Peter
- Jain, Rakesh K.
- ORCID
- Carmeliet, Peter
- Venue
- Nature
- Published
- 2011-05
- Volume
- 473
- Issue
- 7347
- Pages
- 298-307
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4049445
- OpenAlex
- W1992112921
- Semantic Scholar
- cc1723f25e863386b91340ea03cd76a22de359ae
- Cited by
- 5,467
- References
- 100
- Citations by year
- 2026: 238 · 2025: 316 · 2024: 308 · 2023: 364 · 2022: 393 · 2021: 442 · 2020: 399 · 2019: 399 · 2018: 384 · 2017: 454 · 2016: 369 · 2015: 375 · 2014: 326 · 2013: 342 · 2012: 284
- FWCI
- 29.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA115767, R01CA085140, P01CA080124, R01CA126642, R01CA163815)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Oncology › Vascular Tumors and Angiosarcomas
- Keywords
- angiogenesis, angiogenesis inhibitors, vascular endothelial growth factor, VEGF inhibitors, drug resistance, molecular targets, cancer, eye diseases, blood vessel development
- MeSH terms
- Animals, Blood Vessels, Fibroblast Growth Factors, Humans, Platelet-Derived Growth Factor, Transforming Growth Factor beta, Neovascularization, Physiologic, Angiogenesis Inhibitors, Vesicular Transport Proteins, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
